ArticleTranslational andrology and urology2026
Spatial multi-omics reveals a cancer-associated fibroblast-T cell niche sustaining tissue-resident immunity in clear-cell renal cell carcinoma.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clear-cell renal cell carcinoma (ccRCC) has a lot of immune cells in it, but the performance of the body's immune system against ccRCC and the outcome for patients who have ccRCC vary greatly. Recent studies indicate that not only how many immune cells are present, but also the state of those cells and how they are arranged within the tumor microenvironment (TME) contribute to how well an individual's immune system can eliminate ccRCC. Therefore, this study aimed to systematically characterize the spatial organization and functional interactions of immune and stromal cells in ccRCC using integrated single-cell and spatial multi-omics approaches. Methods: To better understand ccRCC through this multi-omics analysis, we utilized two cohort studies of single-cell RNA sequencing (scRNA-seq) data combined with spatial transcriptomics (sRNA-seq) data to make a multi-omics atlas of ccRCC. We performed in-depth functional enrichment analysis, survival analysis, modeling of cell-to-cell communication, as well as spatial validation of these analyses, to identify the heterogeneous nature of cell-cell interactions Results: We identified various epithelial, immune, and mesenchymal cell states in ccRCC, showing distinct differences in their prognostic values: CD4 Trm, iCAFs, PDGFRB Conclusions: These results demonstrate that the prognosis of ccRCC is determined by the spatial organization of the immune-stromal cell niche rather than just by the number of immune cells present. The iCAF-CD4 Trm axes may provide opportunities for precision immunomodulatory therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.